Journal Mobile Options
Table of Contents
Vol. 11, No. 1, 2001
Issue release date: January 2001
Cerebrovasc Dis 2001;11:20–29

Glycine Antagonist (GV150526) in Acute Stroke: A Multicentre, Double-Blind Placebo-Controlled Phase II Trial

Lees K.R. · Lavelle J.F. · Cunha L. · Diener H.C. · Sanders E.A.C.M. · Tack P. · Wester P.
aAcute Stroke Unit, Department of Medicine and Therapeutics, Western Infirmary, Glasgow; bGlaxo Wellcome, Greenford, Middlesex, UK; cHospitais da Universidade de Coimbra, Servicio de Neurologia, Coimbra, Portugal; dKlinikum Neurologie, Universität Essen, Deutschland; eIgnatius Ziekenhuis, Breda, The Netherlands; fDepartment of Neurology, Sint-Andrie Ziekenhuis, Tielt, Belgium; gNorrlands University Hospital, Umeå, Sweden

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


GV150526 is a novel glycine antagonist at the NMDA receptor complex. It is a potent neuroprotective agent in animal models of acute stroke including permanent middle cerebral artery occlusion in the rat. GV150526 was very well tolerated in early human studies. The purpose of this randomised, double-blind, multicentre, placebo-controlled trial was to assess the safety and population pharmacokinetics of GV150526 in patients with a clinical diagnosis of acute stroke. Exploratory assessment of efficacy, quality of life and resource utilisation was also undertaken. Upon clinical diagnosis of acute stroke within 12 h of onset of symptoms, patients were treated with a loading dose of 800 mg GV150526 (or placebo), followed by 5 maintenance doses of 400 mg GV150526 (or placebo) given every 12 h over 3 days. Following observation of asymptomatic hyperbilirubinaemia, the maintenance dose was reduced mid-study to 200 mg. CT/MRI scanning was not mandatory prior to treatment. The study treated 128 patients (38 with GV 800 mg/400 mg, 48 with GV 800 mg/200 mg and 42 with placebo). Fewer patients with mild stroke (NIH scores ≤5) were enrolled in the GV150526-treated groups than in the placebo group (placebo 38%, GV 800 mg/400 mg 18%, GV 800 mg/200 mg 15%). There was also an imbalance in the proportion of patients with haemorrhagic strokes (placebo 5%, GV 800 mg/400 mg 3%, GV 800 mg/200 mg 15%). Mortality at 1 month was unbalanced between treatment groups, being 10, 18 and 17% in the placebo, GV 800 mg/400 mg and GV 800 mg/200 mg groups, respectively (no significant difference). Similarly, adverse events, though consistent with an acute stroke population, appeared more often in the GV 800 mg/200 mg group. Functional outcomes at 1 month also showed imbalances, the percentage of patients with a Barthel Index score of ≧95 at 1 month being 52, 39 and 27% in the placebo, GV 800 mg/400 mg and GV 800 mg/200 mg groups, respectively. These results probably reflect a prognostically significant baseline difference between the groups rather than the effect of GV150526. GV150526 was generally well tolerated in patients with a clinical diagnosis of acute stroke and formal efficacy studies were considered justified.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Ratti E, Corsi M, Carignani C, Cugola A, Nugnaini M, Gaviraghi G, Trist D, Reggiani A: Pharmacological characterisation of the novel glycine antagonist GV150526: In vitro studies. Eur J Neurol 1995;2:57–58.
  2. McCulloch J: Excitatory amino acids antagonists and their potential for the treatment of ischaemic brain damage in man. Br J Clin Pharmacol 1992;34:106–114.
  3. Johnson JW, Ascher P: Glycine potentiates the NMDA response in cultured mouse brain neurones. Nature 1987;325:529–531.
  4. Bardi F, Pietra C, Ziviani L, Reggiani A: The glycine antagonist GV150526 protects somatosensory evoked potential and reduces the infarct area in the MCAO model of focal ischaemia in the rat. Exp Neurol 1997;145:425–433.
  5. Dyker AG, Lees KR: Duration of neuroprotective treatment for ischaemic stroke. Stroke 1998;29:535–542.
  6. Dyker AG, Lees KR, Preston C, Caveggion E: The safety, tolerability and pharmacokinetics of GV150526 in patients with acute stroke. Stroke 1997;28:233.
  7. Hoke JF, Dyker AG, McAllister AM, Lees KR: Pharmacokinetics of GV150526 following multiple intravenous doses in acute stroke patients. Cerebrovasc Dis 1997;7(suppl 4):29.
  8. Wallace M, Cargill K, Lees KR on behalf of the GAIN European Study Group: Resource utilisation assessment of acute stroke treatment (GLYB2002). Cerebrovasc Dis 1999;9(suppl 1):113.
  9. Bamford J, Sandercock P, Dennis M, Warlow C, Jones L, McPherson K, Vessey M, Fowler G, Molyneux A, Hughes T, Burn J, Wade D: A prospective study of acute cerebrovascular disease in the community: The Oxfordshire Community Stroke Project 1981–1986: Methodology, demography and incident cases of first ever stroke. J Neurol Neurosurg Psychiatry 1998;51:1373–1380.
  10. Warlow C, Dennis MS, van Gijn J, Hankey GJ, Sandercock PAG, Bamford J, Wardlaw J: Stroke: A Practical Guide for Management. Bath, Blackwell Science, 1996.
  11. Kapelle LJ, van der Warp HB: Complication of acute ischaemic stroke. Cerebrovasc Dis 1998;8:124–132.
  12. Fogelholm R, Nuutila M, Vuorela AL: Primary intracerebral haemorrhage in the Jyvaskyla region, central Finland, 1985–1989: Incidence, case fatality rate and functional outcome. J Neurol Neurosurg Psychiatry 1995;55:546–552.
  13. Diener HC, Hacke W, Hennerici M, Radberg J, Hantson L, De Keyser J (for the Lubeluzole International Study Group): Lubeluzole in acute ischaemic stroke: A double-blind placebo-controlled phase II trial. Stroke 1996;27:76–81.
  14. Dyker A, Lees KR: Safety and tolerability of GV150526 (a glycine site antagonist at the NMDA receptor) in patients with acute stroke. Stroke 1999;30:986–992.
  15. GAIN Investigators: University of Virginia Neuroclinical Trials Centre and Glaxo Wellcome: Phase II studies of the glycine antagonist, GV150526, in acute stroke (GAIN) preliminary results (poster). 23rd Int Conf Stroke Cereb Circ, Orlando, Fla., 1998.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50